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The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene had been 
isolated as an antagonist to RAS signaling; however the mechanism of its action is not 
clear. In this study, the effect of loss of RECK function was assessed in various ways 
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and cell systems. Successive cell cultivation of MEFs according to 3T3 protocol 
revealed that the germ-line knockout of Reck confers accelerated cell proliferation and 
early escape from cellular senescence associated with downregulation of p19Arf, Trp53 
and p21Cdkn1a. In contrast, shRNA-mediated depletion of RECK induced irreversible 
growth arrest along with several features of the Arf, Trp53 and Cdkn1a-dependent 
cellular senescence. Within two days of RECK depletion, we observed a transient 
increase in AKT and ERK phosphorylation associated with an upregulated expression of 
cyclin D1, p19Arf, Trp53, p21Cdkn1a and Sprouty 2. On further cultivation, RAS, AKT and 
ERK activities were then downregulated to a level lower than control, indicating that 
RECK depletion leads to a negative feedback to RAS signaling and subsequent cellular 
senescence. In addition, we observed that EGFR activity was transiently upregulated by 
RECK depletion in MEFs, and continuously downregulated by RECK overexpression in 
colon cancer cells. These findings indicate that RECK is a novel modulator of EGFR 
signaling. 
 





The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene is a 
negative transcriptional target of various viral oncogenes including activated K-ras 
(Takahashi et al., 1998; Sasahara et al., 1999; Hsu et al., 2006; Liu et al., 2003), and a 
negative post-transcriptional target of oncogenic microRNAs including miR-21 (Hu et 
al., 2008; Gabriely et al., 2008; Zhang et al., 2008; reviewed in Nicoloso et al., 2009; 
Loayza-Puch et al., 2010). Furthermore, histone modification and DNA methylation 
have also been reported to be involved in the transcriptional regulation of RECK (Chang 
et al., 2004; Chang et al., 2006; Chang et al., 2007). RECK expression is frequently 
correlated with a favorable prognosis in patients with various types of cancer (reviewed 
in Clark et al, 2007; Noda and Takahashi, 2007). However, the biological significance 
of these findings and mechanisms underlying them are still unclear. RECK has been 
proposed to be implicated in the extracellular signaling (Morioka et al., 2009), but it is 
not clear which signaling pathway (receptor) is actually influenced by RECK. Although 
Kitajima et al., 
 3 
our previous reports indicated that RECK exerts its functions through interaction with 
matrix metalloproteinases (MMPs) and a disintegrin and metallopeptidase 10 
(ADAM10) (Takahashi et al., 1998; Oh et al., 2001; Miki et al., 2007; Muraguchi et al., 
2007), it is still difficult to determine whether RECK is a bona fide membrane-anchored 
MMP/ADAM inhibitor, or whether MMP/ADAM inhibition is one of its multiple 
functions. We recently identified two RECK domains whose primary structures are 
homologous to that of a common substrate of several MMPs, and these domains were 
very slowly cleaved by the excessive amount of MMPs (Takegami and Takahashi, in 
preparation for publication). This may explain the ability of recombinant soluble RECK 
to competitively inhibit the proteolytic activity of recombinant soluble MMPs or 
membrane type 1-matrix metalloproteinase (MT1-MMP), even though its inhibitory 
effect on these protease activities is weaker than tissue inhibitors of metalloproteinases 
(TIMPs) in in vitro assays (Takahashi et al., 1998; Oh et al., 2001; Miki et al., 2007; 
Omura et al., 2009). 
 
RECK modulates the endocytic pathways of membrane-tethered 
metallo-endopeptidases such as MT1-MMP and CD13/aminopeptidase N (APN) by 
changing their abundance in lipid raft through direct interaction (Miki et al., 2007). This 
appeared to shorten the life span of these membrane-tethered enzymes. Reck-deficient 
mouse embryos show premature differentiation in cortical neurons due to 
downregulated Notch signaling caused by aberrant shedding of Delta-Serrate-Lag2 
(DSL) ligands in an ADAM10-dependent manner (Muraguchi et al., 2007 and reviewed 
in D’Souza et al., 2008; Zolkiewska, 2008). RECK appeared to bind directly to 
ADAM10 and allosterically inhibit its proteolytic activity (Muraguchi et al., 2007). In 
contrast, the recombinant RECK protein has been shown to competitively inhibit MMPs 
(Takahashi et al., 1998; Oh et al., 2001; Miki et al., 2007; Omura et al., 2009). RECK 
and Delta-like family proteins (D’Souza et al., 2008; Zolkiewska, 2008) share 
structurally similar epidermal growth factor (EGF)-like repeats which may serve as 
recognition signals for ADAM10. Although identification of the domains responsible 
for such protein-protein interaction is currently hampered by the extremely cysteine-rich 
primary structure of RECK (Takahashi et al., 1998), these findings suggest that RECK 
may function as more than a protease inhibitor.  
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To further address the basic functions of RECK in cells, in this study, we at first 
compared the short- and long-term effects of germ-line knockout to those of 
shRNA-mediated knockdown of RECK in early passage mouse embryonic fibroblasts 
(MEFs). By shedding light on the differential effects of RECK-deficiency dependent on 
the timing of downregulation, we attempted to identify cell signaling pathways 
modulated by RECK. Previous studies have linked RECK-deficiency to deregulation of 
extracellular gelatinase activities and focal adhesion stability (Oh et al., 2001; Morioka 
et al., 2009); however, these studies employed Reck-deficient MEFs that have been 
cultivated for a long time (more than 35 passages). In this study, we propose that the 
primary effect of RECK-deficiency appears in the control of cell cycle and cellular 
senescence. We identified EGFR/Ras pathway as one of the signaling pathways that are 




Differential effects of germ-line knockout and shRNA-mediated knockdown of RECK 
on cell proliferation 
Consistent with a previous report (Hatta et al., 2009), RECK expression was induced in 
MEFs by serum starvation, and downregulated after release from serum restriction 
(Figure S1a). Moreover, contact inhibition-dependent cell cycle arrest in the presence of 
serum was correlated with the increased RECK expression (Figure S1b). These findings 
implicated involvement of RECK in cell cycle control. In low passage number cell 
cultures, Reck-/- MEFs did not show remarkable differences in growth properties and 
gelatinase activities when compared to wild type or Reck+/- littermates (data not shown). 
However, successive cell cultivation of primary embryonic fibroblasts prepared from 
live embryonic day (E)10.0 embryos according to 3T3 protocol (Todaro and Green, 
1963) revealed that after around 10 passages, Reck-/- MEFs displayed a higher 
proliferation rate, immortal cell growth and smaller cell size in comparison to wild type 
littermates (Figure 1a and data not shown); these findings suggest that germ-line 
knockout of Reck confers accelerated cell proliferation and early escape from cellular 
senescence. These phenotypes were correlated with downregulation of p19Arf, Trp53 and 
p21Cdkn1a (Figure 1b), and suppressed by the forced expression of p21Cdkn1a (Figure 1c).  
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We then attempted to determine the function of RECK in cells by directly depleting 
RECK in wild type MEFs. Opposing to the results of the long-term analysis of 
germ-line knockout MEFs, lentivirus-mediated transduction with RECK-targeted 
shRNAs resulted in marked downregulaton of cell proliferation (Figure 1d). 
Furthermore, RECK depletion in such an acute manner upregulated p19Arf, Trp53, p21 
Cdkn1a and p16Ink4a expression with reciprocal downregulation of Mdm2 within 48 h after 
shRNA transduction (Figure 1e). In the same experiment, we observed slight increase in 
Bax expression; however, we did not detect significant level of apoptosis in 
RECK-depleted MEFs by terminal deoxynucleotidyl transferase-mediated dUTP nick 
end labeling (TUNEL) (data not shown). These findings suggest that RECK controls 
cell proliferation by influencing on the ARF/Tp53/p21Cdkn1a pathway. 
 
We eliminated the possibility of off-target effects by employing multiple sets of shRNA 
and appropriate controls. Moreover, whole cell lysates from live E9.5 Reck-/- embryos 
revealed marked induction of p21 Cdkn1a  (Figure 1f) and reciprocal downregulation of 
bromodeoxyuridine (BrdU) uptake (Figure 1g), both of which account for the smaller 
body size of Reck-nullizygous embryos (Oh et al., 2001), indicating the genetic 
interaction between RECK and the ARF/Trp53/p21Cdkn1a pathway in vivo. Thus far, 
however, we have not found any evidence of either rescued or enhanced lethality in 
Reck-/- embryos at E10.5 by simultaneous Cdkn1a deletion (data not shown). In addition, 
Reck-/-;Cdkn1a-/- MEFs exhibited accelerated proliferation rates, similar to 
Reck+/+;Cdkn1a-/- MEFs on the 3T3 protocol assay (Figure S2). These findings suggest 
that Cdkn1a does not mediate the lethality caused by Reck-deficiency and that the effect 
of deletion of these two genes is not synthetic, i.e., their genetic relationship is linear. 
 
Furthermore, 10 days after RECK depletion, we observed the evidence of cellular 
senescence in MEFs as assessed by increased senescence-associated β-galactosidase 
(SA-β-gal) activity, decreased BrdU uptake, increased p16 Ink4a expression and nuclear 
accumulation of tri-methylated histone H3K9 (H3K9me3) (Figure 1h). We eliminated 
the possibility that RECK depletion induced apoptosis in MEFs even at 10 days after 
shRNA transduction by performing TUNEL staining (data not shown). In addition, we 
observed neither induction nor accumulation of γH2AX in these senesced cells (Figure 
1i), eliminating the possibility that DNA damage response underlies the mechanism of 
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RECK depletion-induced cellular senescence. Additionally, we observed that RECK 
depletion in an adipogenic fibroblast cell line, PA6, caused an arrest of cell growth 
without promoting adipogenic differentiation, as assessed by Oil Red O staining, and 
the induction of PPARγ and C/EBPα (Figure S3a-b), eliminating the possibility that 
RECK depletion may cause premature differentiation in cultured fibroblast cells. In 
addition, we noticed that in contrast to MEFs under serum restriction, RECK is 
downregulated in PA6 cells under differentiation-inducing condition (Figure S3b). 
 
RECK depletion-induced cellular senescence depends on Arf, Trp53 and Cdkn1a but 
not Ink4a  
To study the mechanism by which RECK depletion induces growth suppression and 
cellular senescence, we infected MEFs on various genetic backgrounds with lentivirus 
expressing RECK shRNAs. Arf-/-, Trp53-/- and Cdkn1a-/- but not Ink4a-/- MEFs were 
insensitive to RECK shRNA-induced growth suppression (Figure 2a) and cellular 
senescence (Figure 2b). In Cdkn1a-/- MEFs, we observed that RECK depletion did not 
induce p16Ink4a (Figure 2c), suggesting that p16Ink4a induction by RECK depletion 
depends on Cdkn1a loci. These findings suggest that RECK depletion-induced cellular 
senescence depends on Arf, Trp53 and Cdkn1a. 	 	   
  
RECK depletion induces transient upregulation of AKT and ERK activities through 
the elevation of EGFR activity 
To further clarify the mechanism by which RECK depletion induces growth suppression 
and cellular senescence, we studied the activity of various intra-cellular signaling 
molecules. Since we discovered RECK originally as a gene that antagonized 
Ras-transformation in a cell phenotype-based cDNA screening (Takahashi et al., 1998), 
we particularly focused on Ras signaling. We identified increased phosphorylation of 
AKT and ERK, and upregulated expression of cyclin D1; all these were induced within 
48 h after shRNA-mediated RECK depletion in MEFs (Figure 3a). To investigate the 
mechanism by which RECK functionally interacts with AKT and ERK, we tested 
numbers of inhibitors to various cellular signaling. We first conceived that RECK may 
modulate activity of receptors as we observed in our previous studies (Muraguchi et al., 
2007; Miki et al., 2010). The increased phosphorylation of AKT and ERK induced by 
RECK depletion was sensitive to the receptor tyrosine kinase inhibitor genistein 
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(4',5,7-trihydroxyisoflavone) (Figure S4a). Since genistein inhibits broad range of 
receptor tyrosine kinases and others, we then examined more specific inhibitors. We 
found that gefitinib 
(N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-a
mine), a specific EGFR inhibitor, almost completely recapitulated the results obtained 
by genistein (Figure 3a). Consistent with these results, we observed increased EGFR 
phosphorylation within 2 days of RECK depletion with insignificant change in its 
protein amount (Figure 3b). The increased EGFR activity induced by RECK depletion 
was suppressed by both genistein (Figure S4b) and gefitinib (Figure 3b). These findings 
suggest that RECK depletion in an acute manner induces upregulation of AKT and ERK 
activities through the elevation of EGFR activity. 
 
Mechanism of cellular senescence induced by shRNA-mediated RECK depletion 
The induction of p19Arf, Trp53 and p21Cdkn1a by RECK depletion was sensitive to both 
genistein (Figure S5a) and gefitinib (Figure 4a), indicating that RECK depletion 
upregulated these molecules through EGFR signaling modulation. Moreover, we 
observed that Sprouty 2 upregulation was associated with EGFR activation and 
attenuated by treatment with genistein (Figue S5b) or gefitinib (Figue 4b). Sprouty 2 is 
upregulated by Ras signaling and thereafter antagonizes Ras activation via negative 
feedback mechanism (Courtois-Cox et al., 2006) at multiple points along the Ras 
regulatory pathway (Gross et al., 2001; reviewed in Kim and Bar-Sagi, 2004). We 
monitored AKT and ERK activities in MEFs 10 days after shRNA transduction; as 
expected, these activities were strongly downregulated (Figure 4c). We further observed 
downregulated Ras activity in RECK-depleted cells (Figure 4d), confirming suppression 
of RAS signaling. We examined whether simultaneous depletion of Sprouty 2 is 
sufficient to block the effects of RECK depletion on RAS signaling; however, the result 
was negative (data not shown). We speculated that since the negative feedback 
mechanism to RAS signaling involves more than ten modulators of RAS signaling, i.e., 
several Ras-GAPs, Ras-GEFs, Sprouty and Spred family members, and dual specificity 
phosphatases (DUSPs), simultaneous depletion of solely Sprouty 2 was insufficient to 
antagonize RECK depletion in suppressing RAS signaling.  
 
Furthermore, both genistein (Figue S5c) and gefitinib (Figure 4e) treatment partially but 
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significantly abrogated the negative impact of shRNA-mediated RECK depletion on 
cell growth. Altogether, these findings suggest that shRNA-mediated RECK depletion 
induces transient activation of AKT and ERK by enhancing EGFR activation; however, 
the stimuli to promote cell growth are antagonized by the induction of p19Arf, Trp53 and 
p21Cdkn1a, and the negative feedbacks to the Ras pathway including Sprouty 2 induction, 
subsequently leading to cellular senescence.  
 
Overexpression of RECK attenuates Ras signaling in colon cancer cells  
The abovementioned studies assessed the effects of loss of RECK function. We then 
assessed the effect of gain of RECK function on EGFR signaling. We first attempted to 
reconstitute RECK in Reck-/- MEFs and measure Ras signaling. We infected Reck-/- 
MEFs cultivated for approximately 10 passages with retrovirus vector carrying RECK 
cDNA (Miki et al., 2007), selected with blasticidin, and confirmed physiological level 
expression of RECK. However, we could not detect downregulation of Ras signaling in 
RECK-reconstituted Reck-/- MEFs (data not shown). We speculated that, in contrast to 
RECK depletion which induces irreversible withdrawal from cell cycle, the effect of 
gain of RECK function on Ras signaling in MEFs is reversible and adjustable. We also 
thought that the downregulation of Ras signaling may generate disadvantage in clonal 
expansion during drug selection thus it is difficult to demonstrate.  
 
Nonetheless, we thought that the transient overexpression of RECK may enable us to 
observe its negative impact on RAS signaling. We screened number of 
non-transformaed and cancer-derived cell lines with relatively high 
transfection-competency to find out one that is sensitive to RECK. We finally found that 
transient overexpression of human RECK in SW480 colon cancer cells was sufficient to 
downregulate AKT and ERK activities and cyclinD1 expression, and upregulate 
p21Cdkn1a expression (Figure 5a). In addition, RECK overexpression significantly 
suppressed EGFR activity (Figure 5b). Altogether, the data obtained in this study 
indicate that RECK antagonizes Ras signaling through modulation of EGFR activation. 
 
Treatment of MEFs by EGF and fibroblast growth factor (FGF) strongly attenuated 
RECK expression (Figure S6a), consistent with our previous finding that oncogenic Ras 
attenuates Reck transcription (Takahashi et al., 1998) since both factors are well known 
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to stimulate Ras signaling. Taken together with other results, we propose that the RECK 
and Ras signals are mutually suppressing (Figure S6b). 
 
Mechanism of the RECK-EGFR genetic interaction 
Finally, we addressed the mechanistic aspects of the RECK-EGFR genetic interaction. 
The exogenous introduction of wild type RECK-expression vector that is insensitive to 
our RECK shRNAs antagonized the effect of endogenous RECK depletion on cell 
growth (Figure 6a-b). This again eliminated the possibility that the effects of RECK 
shRNAs on cell proliferation were the product of off-target effects. Interestingly, in the 
same setting, secreted form of RECK (RECKΔC: one mutant lacking the membrane 
anchor) was unable to antagonize RECK shRNAs, indicating that membrane-anchoring 
is required for RECK modulation of cell growth mediated by Ras signaling (Figure 
6a-b). We have thus far been unable to detect a direct interaction between RECK and 
EGFR (data not shown).  
 
Next, we hypothesized that increased metallo-endopeptidase activities induced by 
RECK loss may affect cell growth and Ras signaling in MEFs. However, a broad 
spectrum (non-specific) metallo-endopeptidase inhibitor, GM6001, did not show 
antagonism to Ras signaling activation and growth arrest induced by RECK depletion 
(Figure 7a-b). Then, we assessed specifically the MMP-2 and MT1-MMP-dependency 
of RECK function in Ras signaling modulation, as it had been previously addressed in 
the context of embryonic development (Oh et al., 2001), endocytosis (Miki et al., 2007) 
and vascular development (Miki et al., 2010). We first examined whether germ-line loss 
of MMP-2 or MT1-MMP antagonizes RECK depletion-induced growth suppression. 
Both MMP-2-/- MEFs and MT1-MMP-/- MEFs exhibited partial but significant resistance 
to RECK depletion-induced growth suppression (Figure 7c). More importantly, 
suppression of RAS signaling by RECK depletion was significantly lesser in those 
MEFs than in wild type (Figure 7d). These findings suggest that MT1-MMP/MMP-2 
system may mediate RECK to modulate EGFR signaling.   
 
We finally addressed whether in other lineage of cells, RECK depletion-induced cellular 
senescence associates with Ras signaling downregulation in an MMP-2-dependent 
manner. Human umbilical endothelial cells (HUVECs) express MMP-2 (Jodele et al., 
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2006). Our recent study has demonstrated that siRNA-mediated RECK depletion in 
HUVECs induced proliferation defects and abnormal vascular development in part in an 
MMP-2-dependent manner (Miki et al., 2010). In consistent with our current study 
using MEFs, siRNAs targeting RECK induced upregulation of Sprouty 2, and reciprocal 
downregulation of ERK activity in HUVECs at 3 days after transduction; these were 
significantly antagonized by simultaneous introduction of MMP-2 siRNAs (Figure S7a). 
In consonance, the growth suppression in HUVECs induced by RECK depletion was 
partially antagonized by simultaneous MMP-2 depletion (Figure S7b). These findings 
suggest a specific role of MMP-2 in the RECK-EGFR genetic interaction in multiple 




In this study, the functions of RECK in cultured cells (MEFs, colon cancer cells and 
vascular endothelial cells) and embryos were assessed by a variety of ‘loss of function’ 
and ‘gain of function’ investigations. We concluded that RECK antagonizes Ras 
signaling via attenuating EGFR activation in multiple cell lineages. The precise 
mechanism of the RECK-EGFR genetic interaction and its dependency on MMP-2 and 
MT1-MMP is currently under intensive investigation. MMP-2 or MT1-MMP may 
indirectly influence on the ectodomain shedding of membrane-tethered growth factors 
binding to EGFR family members that is thought to be mediated by a disintegrin and 
metalloprotease (ADAM) members. However, so far, we did not observe change in the 
degree of ectodomain shedding of EGFR family ligands (TGFα, EGF, HB-EGF, 
Betacellulin, Amphiregulin and Epiregulin) by modulating RECK expression (data not 
shown), and we so far did not detect direct binding of RECK and EGFR.  
 
Despite the marked induction of p21Cdkn1a observed in whole embryos, MEFs separated 
from E10.0 Reck-/- embryos expressed p21Cdkn1a at a level comparable to wild type cells, 
suggesting that Reck-deficiency causes a certain stress to the whole body, leading to 
p21Cdkn1a induction, or that p21Cdkn1a level had been quickly adjusted to normal level 
under in vitro culture conditions during 3 passages. Acquirement of accelerated and 
immortal cell proliferation by Reck-/- MEFs during successive cell cultivation was 
closely correlated with attenuated p19Arf, Trp53 and p21Cdkn1a expression.  In contrast, 
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RECK depletion-induced cellular senescence required the presence of these loci. These 
seemingly self-contradicting findings helped us to conceive that the cellular signaling 
modulated by RECK could be bivalent in the control of cell proliferation. We then 
noticed that the notion of ‘oncogene-induced senescence’ (Collado and Serrano, 2010) 
and its revised version notion ‘negative feedback to Ras signaling’ (Courtois-Cox et al., 
2008) may explain our findings.  
 
Cellular senescence induced by oncogenic Ras has been proposed to be mediated by 
DNA hyper-replication and following DNA damage response (Bartkova et al., 2006; Di 
Micco et al., 2006); this may explain RECK depletion-induced cellular senescence. 
However, we eliminated this possibility by investigating several markers of DNA 
damage response including γH2AX (Figure 1i) and phosphorylated Trp53S15 (data not 
shown) in RECK-depleted MEFs. Also, the positive sensitivity of Ink4a-/- MEFs to 
RECK depletion-induced cellular senescence may imply that the nature of Ras 
activation induced by RECK depletion differs from that of oncogenically mutated Ras. 
We further speculate that DNA damage may be prerequisite for p16Ink4a-dependent but 
not for ARF/p53/p21Cdkn1a -dependent cellular senescence induced by oncogenic stimuli.   
 
The relationship between RECK and Sprouty 2 is highly similar to that initially noted 
between the Neurofibromatosis type 1 (NF1) tumor suppressor gene and Sprouty 2 
(Courtois-Cox et al., 2006). NF1 is a member of the Ras GTPase activating proteins 
(RasGAPs) that suppresses Ras activation by promoting hydrolysis of GTP (reviewed in 
Cichowski and Jacks, 2001). Activation of Ras signaling induced by NF1 inactivation 
provokes a series of negative feedback loops to Ras pathways by inducing the 
transactivation of many of antagonists to Ras signaling pathway including the Sprouty 
(suppressor of Ras) and SPRED (Sprouty-related protein) family members, and many of 
RasGAPs and dual specificity phosphatases (DUSPs), in an AKT/FOXO- and 
Rb/Trp53-dependent manner (Courtois-Cox et al., 2006). Cichowski’s research group 
thereby revised the “oncogene-induced cellular senescence model” (Serrano et al., 
1997) by proposing this negative feedback mechanism (Bardeesy and Sharpless, 2006). 
We observed this mechanism in cells that acutely lost RECK function, highlighting the 
tumor suppressor trait of RECK gene more clearly than ever. We also speculate that in 
contrast to the shRNA-mediated RECK depletion, the germ-line RECK knockout 
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allowed cells to take enough time to override growth-suppressing signals involving 
negative feedback pathway before cellular senescence program was engaged. We are 
currently examining whether early escape from cellular senescence by Reck-/- MEFs 
depends on EGFR function.   
 
The strong clinical relevance of the tumor suppressor trait of RECK gene had been 
previously provided by a couple of studies that reported strong correlations between 
RECK expression and favorable prognosis for patients with non-small-cell lung cancer 
(NSCLC) (Takenaka et al., 2004; Takenaka et al., 2005) whose malignant behaviors 
critically depend on EGFR signaling (reviewed in Andratschke et al., 2004; Jänne et al., 
2005). In addition to NSCLC, RECK significantly predicts favorable prognosis in many 
types of cancer including colorectal cancer (Rahmah et al., 2009; Long et al., 2008; 
Takemoto et al., 2007; Rabien et al., 2007; refs in Clark, 2007; refs in Noda and 
Takahashi, 2007). Our current study demonstrated that RECK attenuates AKT and ERK 
in the SW480 colon cancer cell line overriding the activating mutation in K-ras 
harbored by this cell line (Anker et al., 1994). We originally identified RECK as a gene 
product whose overexpression dominantly antagonizes oncogenic K-ras-induced 
transformation (Takahashi et al., 1998). Altogether, our current study suggests that 
RECK antagonizes both physiological and oncogenic Ras signaling.  
 
RECK transcription is suppressed by oncogenic Ras (Takahashi et al., 1998). As 
expected, the treatment of cells with EGF and FGF strongly suppressed RECK 
expression in cell culture (Figure S6a). In this study, mutual suppression between RECK 
and Ras signaling was demonstrated (Figure S6b). In addition, many of retroviral 
oncogenes (Takahashi et al., 1998), oncogenic DNA virus products (Liu et al., 2003) 
and the so-called ‘oncomir’ (oncogenic microRNA) miR-21 (Hu et al., 2008; Gabriely 
et al., 2008; Zhang et al., 2008; Loayza-Puch et al., 2010; reviewed in Nicoloso et al, 
2009) were demonstrated to negatively regulate RECK transcription. These findings 
indicate that these oncogenic signals may commonly impact on Ras signaling from the 
extracellular space via transcriptional regulation of RECK.  
 
It was demonstrated that MMP-9 is transcriptionally regulated by RECK via 
transcription factors Fra-1 and c-Jun through 12-O-tetradecanoylphorbol-13-acetate 
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(TPA)-responsive (TRE)-1 site in the MMP-9 promoter (Takagi et al., 2009). Fra-1 and 
c-Jun are highly established downstream targets of EGFR signaling, and MMP-9 is 
indeed upregulated by EGF (Lyons et al., 1993). There is a possibility that RECK 
directs MMP-9 transcription by modulating EGFR signaling. In addition, we recently 
determined that RECK is a direct substrate of several MMP activities (Takegami et al., 
in preparation for publication). It is possible that MMP activities enhance Ras signaling 
even by impairing RECK functions. We further speculate that RECK may function as a 
converter of extracellular protease activities to Ras signaling. 
 
Finally, this study demonstrated that like loss of Phosphatase and Tensin Homolog 
Deleted from Chromosome 10 (PTEN), NF1 or Von Hippel-Lindau disease (VHL) tumor 
suppressor genes (Chen et al., 2005; Courtois-Cox et al., 2006; Young et al., 2008), or 
activating mutation in several Ras isoforms or B-Raf (Braig et al., 2005; Michaloglou et 
al., 2005), the effect of loss of RECK function on cell proliferation is counteracted by 
the cellular senescence program. Furthermore, we have recently reported that 
carcinogenesis induced by loss of the Retinoblastoma (Rb) tumor suppressor gene is 
antagonized by DNA damage response and cellular senescence induced by 
E2F-depednent activation of N-Ras (Shamma et al., 2009). Therefore, we speculate that 
signals antagonistic to loss of many tumor suppressors may commonly converge on Ras 
signaling.    
 
Materials and Methods	 	 	  
 
Mice 
Reck+/- mice (Oh et al., 2001) were backcrossed to C57BL/6 mice for 6 generations, and 
intercrossed for timed pregnancy. Arf knockout mice were gifted from T. Kamijo 
(Kamijo et al., 1997). Trp53 knockout mice (Tsukada et al., 1993) were obtained from 
RIKEN BRC (Acc. No. CDB0001K). Cdkn1a knockout mice were gifted from P. Leder 
(Deng et al., 1995). Ink4a knockout mice were from N. Sharpless (Sharpless et al., 
2001). MMP2 knockout mice were from S. Itohara (Itoh et al., 1997) and MT1-MMP 
knockout mice were from Y. Okada and M. Seiki (Oh et al., 2004). Animals were 
handled in accordance with the guidelines of Kyoto University and Kanazawa 
University.   
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Generation of MEFs 
Primary MEFs were prepared as described previously (Shamma et al., 2009) from 
individual embryos of various genotypes, and maintained in α-Modified Eagle’s 
Medium (α-MEM) supplemented with 10% fetal bovine serum (FBS). Primary MEFs 
were used for each experiment before 10 passages.  
 
3T3 protocol 
2 x 105 cells were plated in 60 mm diameter dishes. After 3 days, the total number of 
cells in each dish was counted using a particle counter (Coulter Counter Z1, Beckman 
Coulter), and 2 x 105 cells were re-plated into the 60 mm diameter dishes. This 
procedure was repeated every 3 days for 20~30 passages. 
 
Retrovirus and plasmids 
Retroviruses were recovered from Ecopack293-2 (Clontech) transfected with pLXSB, 
pLXSB-human RECK (hRECK) (Miki et al., 2007), pLXSB-hRECKΔC (Takahashi et 
al., 1998), pBabe-puro, and pBabe-puro-p21. MEFs were plated 20 h before infection, 
and infected with virus in the presence of 8 µg/ml polybrene. The estimated multiplicity 
of infection (MOI) was 2 to 3. Twenty-four hours after infection, infected cells were 
selected in the presence of 8 µg/ml blasticidin or 2 µg/ml puromycin.  
 
RNA interference 
MISSION TRC shRNA target sets for mouse RECK (sh-RECK #1: TRCN80129 and 
sh-RECK #2: TRCN80131), those targeting Luciferase (sh-Luciferase: SHC007) and 
negative control (sh-Negative control: SHC002) were purchased from Sigma-Aldrich. 




Cells were plated on 96 well-type plates (1 x 103 cells/well). After shRNA-lentivirus 
infection, the cell numbers were quantified by colorimetric assay using Cell count 
reagent SF (07553-15, Nacalai tesque, Japan) according to the manufacturer’s 
instructions.  
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Immunoblotting and Immunofluorescence  
Immunoblotting and immunofluorescence were performed in buffer (Miki et al., 2007) 
or in acid-extraction buffer (Shamma et al., 2009) as described previously using the 
following antibodies: p19Arf (#07-543, Upstate), Trp53 (1C12, Cell Signaling 
Technology), p21CDKN1A (#556430, BD bioscience), α-Tubulin (Ab-1, Calbiochem), 
RECK (Miki et al., 2007), Mdm2 (4B11, Calbiochem), Bax (sc-493, Santa Cruz	 
Biotechnology), p16 INK4a (sc-1207, Santa Cruz	 Biotechnology), H3K9me3 (#07-442, 
Upstate), γH2AX (#05-636, Upstate), Phosphorylated AKT (#9271, Cell Signaling 
Technology), Total-AKT (#9272, Cell Signaling Technology), Phosphorylated ERK1/2 
(#9101, Cell Signaling Technology), Total-ERK1/2 (#9102, Cell Signaling Technology), 
cyclinD1 (DCS6, Cell Signaling Technology), EGFR (#06-847, Upstate), Sprouty 2 
(sc-30049, Santa Cruz Biotechnology), and Ras (#610002, BD bioscience). 
 
BrdU incorporation 
Cultured cells were incubated with 10 µM BrdU for 60 min. The in utero BrdU labeling 
of E10.0 embryos was performed as described previously (Muraguchi et al., 2007). For 
embryo labeling, the tissue was dispersed by 0.25 % Trypsin/EDTA for 5 min at room 
temperature. Samples were stained using the BrdU Labeling and Detection Kit l 
(Cat.No.1 296 736, Roche Diagnostics) according to the manufacture’s instructions. 
Data were collected using FACS Aria (BD Biosciences). 
 
SA-β-gal staining 
Cells were fixed with 0.2 % glutaraldehyde and 0.2 % formaldehyde in 
phosphate-buffered saline (PBS) (pH7.5), and stained in SA-β-gal solution (1 mg/ml 
X-gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, and 2 mM MgCl2 in PBS (pH6.0) ) for 12 h 
at 37 OC. 
 
Immunoprecipitation 
Cell lysates were prepared as described previously (Miki et al., 2007). Proteins with 
phosphorylated tyrosine were immunoprecipitated using anti-phosphorylated Tyrosine 
(pTyr) antibody (PY99, Santa Cruz Biotechnology). The immunoprecipitates were 
collected on protein A-agarose beads (20334, Pierce), washed 5 times with lysis buffer, 
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eluted, and analyzed by immunoblotting. 
 
Ras activation assay 
Cell lysates were prepared as described previously (Shamma et al., 2009). 500 µg of the 
lysates were incubated with the Ras binding domain (RBD) of cRaf-1 fused to 
glutathione S-transferase (GST) to precipitate GTP-loaded Ras. Glutathione-Sepharose 
4B (17-0756-01, GE healthcare) beads were preloaded with GST-RBD. After incubation 




Cells were transfected with pCXN2, or pCXN2-hRECK (Takahashi et al., 1998) using 
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Figure 1  Effects of germ-line knockout and shRNA-mediated depletion of RECK 
in MEFs. 
(a) 3T3 protocol assay of MEFs of the indicated genotypes. WT: wild type littermate.  
Cumulative multiplicity (log10) in the representative cultures at the indicated passage 
numbers is shown.  
(b) Immunoblotting (IB) of the indicated proteins in MEFs of the indicated genotype at 
passage number 3 (upper) and 15 (lower).	   
(c) Reck-/- MEFs at passage number 22 were retrovirally transduced with pBabe-puro or 
pBabe-puro-p21CDKN1A and selected. The 3T3 protocol assay of the resultant cells is 
shown (left). IB of the indicated proteins in the resultant cells (right).  
(d) Relative number of MEFs lentivirally transduced with the indicated shRNAs and 
cultured for 5 days was quantified by colorimetric assay. Bars are means ± SEM (n = 3). 
(e) IB of the indicated proteins in whole cell lysates from MEFs transduced with the 
indicated shRNAs and cultured for 48 h.  
(f) IB of the indicated proteins in E9.5 mouse embryos of the indicated genotype. Three 
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pairs of littermate were analyzed.  
(g) BrdU incorporation by E10.0 mouse embryos. Bars are means + SEM (n = 5 
embryos of each genotype). *P < 0.01 by Student’s t-test. 
(h) Upper panels show SA-β-gal activity and BrdU incorporation in MEFs at 10 days 
after transduction with the indicated shRNAs (left). The frequency of cells with positive 
signal was quantified (right). Lower panels show immunofluorescence (IF) analysis of 
the indicated proteins in MEFs at 10 days after transduction with the indicated shRNAs. 
The frequency of cells with positive signal was quantified (right). Scale bar: 100 µm. 
Bars are means + SEM (n = at least 10 fields). The insets show high-power 
magnification pictures of signal-positive cells. Non: Non-Target. 
(i) IF analysis of γH2AX in MEFs at 48 h after transduction with the indicated shRNAs. 
UV: Ultra Violet (germicidal lamp)-exposed for 30 min as positive control of DNA 
damage response.	 Scale bar: 100 µm. The insets show high-power magnification 
pictures of signal-positive cells. 
 
Figure 2  Effects of shRNA-mediated RECK depletion on MEFs of different 
genetic backgrounds. 
(a) Relative cell numbers of the indicated genotype of MEFs were quantified at 5 days 
after transduction with the indicated shRNAs. Bars are means + SEM (n = 3). *P < 0.01 
by Student’s t-test.   
(b) SA-β-gal activity was detected (left) and quantified (right) in MEFs of the indicated 
genotype at 10 days after transduction with the indicated shRNAs. Scale bar: 200 µm. 
Bars are means + SEM (n = at least 10 fields). 	 	 	   
(c) IB of the indicated proteins in whole cell lysates from the indicated genotype of 
MEFs transduced with the indicated shRNAs and cultured for 48 h.  
 
Figure 3  Effects of shRNA-mediated RECK depletion on EGFR signaling in 
MEFs. 
(a) IB of the indicated proteins in wild type MEFs transduced with the indicated 
shRNAs and cultured for 48 h in the presence of 0.1 % dimethyl sulfoxide (DMSO) 
(vehicle) or 1 µM gefitinib (S1025, Selleck Chemicals).  
(b) Immunoprecipitation from whole lysates of cells from panel (a) with an 
anti-phosphorylated Tyrosine (pTry) antibody. Precipitates from 500 µg protein in 
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whole cell lysates  (upper) or 20	 µg	 protein in whole cell lysates (lower) were 
analyzed by IB with anti-EGFR antibody. 
 
Figure 4  Negative feedback to RAS signaling induced by shRNA-mediated 
RECK depletion. 
(a, b) IB of the indicated proteins in wild type MEFs transduced with the indicated 
shRNAs for and cultured for 48 h in the presence of 0.1 % DMSO (vehicle) or 1 µM 
gefitinib. 
(c) IB of the indicated proteins in whole cell lysates from MEFs transduced with the 
indicated shRNAs and cultured for 10 days.   
(d) Pull-down of GTP-loaded Ras from 500 µg protein in whole cell lysates (upper) or 
20	 µg	 protein in whole cell lysates (lower) were analyzed by IB with anti-Ras 
antibody. Whole cell lysates were prepared from MEFs transduced with the indicated 
shRNAs and cultured for 48 h. 
(e) Relative numbers of MEFs at 5 days after transduction with the indicated shRNAs 
and treatment with 0.1 % DMSO (vehicle) or 1 µM gefitinib were quantified. Bars are 
means + SEM (n = 3). *P < 0.01 by Student’s t-test.	  
 
Figure 5  Effects of RECK overexpression on EGFR signaling in colon cancer 
cells. 
(a) SW480 cells were transiently transfected with pCXN2 (Vector) or pCXN2-human 
RECK  cDNA (RECK) and cultured for 48 h. The expression of the indicated proteins 
in asynchronously growing transfectants was analyzed by IB. 
(b) Immunoprecipitation from whole lysates of cells from panel (a) with an anti-pTyr 
antibody. Precipitates from 500 µg protein in whole cell lysates  (upper) or 20	 µg	 
protein in whole cell lysates (lower) were analyzed by IB with anti-EGFR antibody. The 
relative activity of EGFR (phophorylated form per total) is quantified and indicated as 
control set to 1.0.  
 
Figure 6  The membrane-anchoring-dependent function of RECK. 
(a) RECK expression in MEFs retrovirally transduced with pLXSB, pLXSB-hRECK or 
pLXSB-RECKΔC and selected was analyzed by IB. WCL: whole cell lysates.  
(b) Cells from panel (a) were then transduced with the indicated shRNAs. Relative cell 
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number was quantified at 5 days after transduction. Bars are means + SEM (n = 3). *P < 
0.01 by Student’s t-test. 
 
Figure 7  The MMP-2 and MT1-MMP-dependent effect of RECK depletion on 
MEFs. 
(a) IB of the indicated proteins in whole cell lysates from MEFs transduced with the 
indicated shRNAs and cultured for 48 h in the presence of 10µM GM6001 negative 
control (an ineffective analogue: #364210, Calbiochem) or 10 µM GM6001 (#364205, 
Calbiochem). 
(b) MEFs transduced with the indicated shRNAs were incubated in growth medium 
containing either 10µM GM6001 negative control or 10µM GM6001. Relative cell 
number was counted at 5 days after transduction of the indicated shRNAs. Bars are 
means + SEM (n = 3).  
(c) Cell proliferation of the indicated genotype of MEFs infected with lentivirus 
expressing the indicated shRNAs. Resultant cells were plated at 2 x 105 cells onto 60 
mm dish, cultured for 4 days and photographed (left), and numbers of cells were 
quantified (right). Scale bar: 250 µm. Bars are means + SEM (n = 4 fields). *P < 0.01 
by Student’s t-test.  
(d) IB of the indicated proteins in whole cell lysates from the indicated genotype of 
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Supplemental Materials and Methods 
 
Induction of adipogenesis   
An adipogenic fibroblast cell line PA6 was obtained from RIKEN BRC (RCB1127). 
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The cells  were maintained in α-modified Eagle's medium (αMEM) supplemented 
with 10% fetal bovine serum (FBS), plated at a density of 1x104/cm2,	 and allowed to 
differentiate for 7 days in an differentiation-inducing medium containing 0.25 µM 
dexthametasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and 10 µg/ml insulin. 
 
Oil Red O staining 
Cells were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) 
for 30 min, rinsed with PBS and then by 60 % isopropanol, stained with 30 mg/ml Oil 
Red O (Sigma) in 60% isopropanol, and again rinsed with PBS.    
 
Antibody and reagent 
Immunoblotting was performed using the following antibodies: p27CDKN1B (sc-528, 
Santa Cruz Biotechnology), PPARγ (sc-7273, Santa Cruz Biotechnology), and 
C/EBPα (sc-61, Santa Cruz Biotechnology). 
 
Cell culture 
The human umbilical vein endothelial cells (HUVECs: CC2517, CAMBREX) were 
maintained in EGM-2 bullet kit (CC-3162, CAMBREX). HUVECs were used for each 
experiment before 5 passages. 
 
RNA interference 
The siRNAs specifically targeting human RECK (si-RECK #1: 29149, si-RECK #2: 
29155) and negative control (4611G) were purchased from Ambion, and those targeting 
human MMP-2 (1178208) were purchased from Invitrogen. 5 x 104 HUVECs were 
transfected with 50 mM siRNAs using Lipofectamine2000 (Invitrogen). 
 
Legends for supplemental figures 
 
Figure S1  RECK expression in MEFs upon serum starvation, release from 
starvation and contact inhibition.  
(a) MEFs were incubated in αMEM containing 0.1% fetal bovine serum (FBS) for 3 
days, and exposed to 10 % FBS for the indicated period of time. The expression of the 
indicated proteins was analyzed by IB at the indicated time point. 
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(b) MEFs were plated at 0.3 x 105  (low density), 1 x 105 (subconfluent) or 2 x 105 
(confluent) (cells per 6 well-type plate), and collected after incubation for 24 h. The 
expression of the indicated proteins in resultant cells was analyzed by IB.   
 
Figure S2  Impact of RECK-Cdkn1a double knockout on cell proliferation. 
MEFs of the indicated genotype were analyzed using the 3T3 protocol. 
  
Figure S3  Effects of acute RECK depletion on differentiation of the adipogenic 
fibroblast cell line PA6. 
(a-b) Close-to-confluent (2 x 105 cells per 6 well-type plate) PA6 cells lentivirally 
transduced with the indicated shRNAs were cultured in growth medium for 24 h, after 
which cells were incubated in differentiation-inducing medium for 7 days. The resultant 
cells were stained with Oil Red O and photographed under light microscopy (a). The 
expression of the indicated proteins in cells treated as indicated was analyzed by IB (b). 
 
Figure S4  Effects of shRNA-mediated RECK depletion on EGFR signaling in 
MEFs. 
(a) IB of the indicated proteins in wild type MEFs transduced with the indicated 
shRNAs and cultured for 48 h in the presence of 0.1 % dimethyl sulfoxide (DMSO) 
(vehicle) or 10 µM genistein (345834, Calbiochem).   
(b) Immunoprecipitation from whole lysates of cells from panel (a) with an 
anti-phosphorylated Tyrosine (pTry) antibody. Precipitates from 500 µg protein in 
whole cell lysates  (upper) or 20	 µg	 protein in whole cell lysates (lower) were 
analyzed by IB with anti-EGFR antibody. 
 
Figure S5  Negative feedback to RAS signaling induced by acute RECK 
depletion. 
(a, b) IB of the indicated proteins in wild type MEFs transduced with the indicated 
shRNAs for and cultured for 48 h in the presence of 0.1 % DMSO (vehicle) or 10 µM 
genistein. 
(c) Relative numbers of MEFs at 5 days after transduction with the indicated shRNAs 
and treatment with 0.1 % DMSO (vehicle) or 10 µM genistein were quantified. Bars are 
means + SEM (n = 3). *P < 0.01 by Student’s t-test.	  
Kitajima et al., 
 4 
 
Figure S6  Effects of EGF and FGF on RECK expression in MEFs. 
(a) MEFs treated with 10 ng/ml EGF or 10 ng/ml FGF for 24 h in the presence of 10 % 
FBS were analyzed by IB for the indicated proteins.    
(b) A model of the genetic interaction of RECK and RAS signaling.	  
 
Figure S7  MMP-2 dependent effects of RECK depletion in HUVECs. 
(a) IB of the indicated proteins in whole cell lysates from HUVECs transfected with the 
indicated siRNAs and cultured for 3 days. Figure  
(b) Cell proliferation of HUVECs transfected with the indicated siRNAs. Cells were 
plated at 5 x 104 cells per 6 well-type plate, cultured for 48 h, and photographed under 
light microscopy (left). The cell number of HUVECs transfected with the indicated 
siRNAs was quantified (right). Scale bar: 500 µm. Bars are means + SEM (n = 4 fields). 
*P < 0.01 by Student’s t-test. 
 
 
 
 
 







